Policy
The FDA has launched proof-of-concept real-time clinical trials with AstraZeneca and Amgen, signaling a fundamental shift in how drug development data is monitored and regulatory decisions are made.
Pharmaceuticals
Teva Pharmaceutical Industries' $700 million acquisition of Emalex Biosciences brings ecopipam, a first-in-class D1 receptor antagonist, to pediatric Tourette syndrome treatment—challenging decades of dopamine D2-targeting therapy.
Pharmaceuticals
Sun Pharmaceutical's $11.75 billion acquisition of Organon marks a watershed moment in global pharmaceutical consolidation. The deal reveals how Indian drugmakers are evolving from generics suppliers into genuine global players, while exposing the structural pressures reshaping the industry.
Biotechnology
On April 23, 2026, the FDA granted accelerated approval to Regeneron's Otarmeni, the first gene therapy ever approved for genetic hearing loss—a breakthrough that represents a categorical shift in what medicine can do.
Biotechnology
Regeneron's Phase 3 NIMBLE trial data for cemdisiran demonstrates a paradigm shift in myasthenia gravis treatment. A quarterly subcutaneous injection achieves meaningful clinical outcomes with a favorable safety profile, potentially redefining patient care in this chronic neuromuscular disorder.
Policy
Trump's executive order fast-tracking FDA review of psychedelic drugs like psilocybin and ibogaine signals a major shift for mental health treatment and the biotech sector.
Biotechnology
Novartis CEO Vas Narasimhan's appointment to Anthropic's board marks a significant shift in pharmaceutical industry governance of AI technology, signaling that pharma is becoming a co-author of AI governance norms.
Biotechnology
Spyre Therapeutics' Phase 2 data for SPY001 demonstrates a credible challenge to Takeda's Entyvio blockbuster, with superior remission rates and the potential for quarterly or biannual dosing in ulcerative colitis treatment.
Biotechnology
Revolution Medicines' pan-RAS inhibitor daraxonrasib delivered a median overall survival of 13.2 months in metastatic pancreatic cancer—nearly doubling survival compared to standard chemotherapy. This Phase 3 breakthrough could reshape treatment paradigms for RAS-driven cancers.
Pharmaceuticals
The FDA faces its PDUFA deadline today on Travere Therapeutics' FILSPARI (sparsentan) for FSGS. If approved, it would be the first-ever therapy indicated for this rare, devastating kidney disease affecting 40,000 Americans.
Policy
Steve Ubl's announcement that he will step down as president and CEO of PhRMA signals that the political architecture the pharmaceutical industry built over the past decade is under unprecedented stress.
Pharmaceuticals
Novo Nordisk launched Wegovy HD at $399 per month, undercutting Lilly's Zepbound by $50. The move signals a new phase in the GLP-1 market where pricing strategy and clinical differentiation are becoming inseparable.